Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHe HuangWZWeiyan Zheng

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows high response rate of 97% in adult patients with acute myeloid leukemia, indicating reduced toxicity with venetoclax.

Key Points

  • Overall response rate reached 97% after two cycles of IA + VEN treatment in adult patients.
  • Median event-free survival was 34.4 months among patients, suggesting potential long-term benefits.
  • Retrospective analysis assessed the effectiveness of administering Idarubicin and venetoclax in this patient cohort.
  • Lower cardiac toxicity was observed with the reduced intensive regimen, supporting safer treatment options for AML.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5bahttps://doi.org/10.1182/blood-2025-6908
View Full Paper
Ask AI
Bookmark
Share